Detalhe da pesquisa
1.
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 627(8004): 646-655, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418879
2.
B cells are associated with survival and immunotherapy response in sarcoma.
Nature
; 577(7791): 556-560, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31942077
3.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38816613
4.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 627(8005): E11, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38480897
5.
Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study.
Mol Cancer
; 23(1): 37, 2024 02 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38374062
6.
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
Mol Cancer
; 23(1): 38, 2024 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38378555
7.
Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.
Cancer
; 2024 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38824658
8.
Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?
Oncologist
; 29(5): 452-455, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38558248
9.
Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens.
Oncologist
; 29(6): 465-472, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630538
10.
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
N Engl J Med
; 384(25): 2371-2381, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34096690
11.
EWSR1::WT1 Fusions in Neoplasms Other Than Conventional Desmoplastic Small Round Cell Tumor: Three Tumors Occurring Outside the Female Genital Tract.
Mod Pathol
; 37(3): 100418, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38158126
12.
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
Future Oncol
; 20(3): 113-120, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38010044
13.
Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers.
Lab Invest
; 103(5): 100063, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36801637
14.
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Mol Cancer
; 22(1): 176, 2023 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37924050
15.
REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.
Mol Cancer
; 22(1): 127, 2023 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37559050
16.
Pain in desmoid-type fibromatosis: Prevalence, determinants and prognosis value.
Int J Cancer
; 153(2): 407-416, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883417
17.
Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.
BMC Cancer
; 23(1): 69, 2023 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36670431
18.
Distinct patterns of the natural evolution of soft tissue sarcomas on pre-treatment MRIs captured with delta-radiomics correlate with gene expression profiles.
Eur Radiol
; 33(2): 1205-1218, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36029343
19.
Prognostic factors of the synovial sarcoma of the extremities: imaging does matter.
Eur Radiol
; 33(2): 1162-1173, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35980435
20.
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Lancet Oncol
; 23(8): 1044-1054, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35835135